The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
* This Week in the Journal
 May 22, 2008
 Audio Icon Audio Summary
*
Correspondence
* Severe Anemia in Malawian Children
* Multifactorial Intervention and Mortality in Type 2 Diabetes
* Iron-Overload–Related Disease in HFE Hereditary Hemochromatosis
* Catheter Ablation in Patients with ICDs
* Athletes with Repolarization Abnormalities
* Neurogenic Orthostatic Hypotension
* A PCSK9 Missense Variant Associated with a Reduced Risk of Early-Onset Myocardial Infarction
*
Book Reviews
* Comprehensive Pediatric Hospital Medicine
* Popular Medicines: An Illustrated History
* Psychoanalysis and Narrative Medicine
* Musicophilia: Tales of Music and the Brain
*
Continuing Medical Examination
* Facilitated PCI in Patients with ST-Elevation Myocardial Infarction
* Sublingual Immunotherapy
* Case 16-2008: A 46-Year-Old Woman with Bone Pain
Original Articles
Facilitated PCI in ST-Elevation Myocardial Infarction

Immediate percutaneous coronary intervention (PCI) is the treatment of choice for acute ST-segment elevation myocardial infarction. In this study, PCI that was "facilitated" by pretreatment with reteplase plus abciximab or abciximab alone did not improve clinical outcomes and increased bleeding, calling into question the use of facilitated PCI for the treatment of acute myocardial infarction.

Related Editorial


Original Articles
Bivalirudin during PCI for Acute Myocardial Infarction

Bivalirudin is a direct thrombin inhibitor. As compared with a combination of heparin and a glycoprotein IIb/IIIa inhibitor, bivalirudin use resulted in less bleeding and lower 30-day mortality among patients undergoing PCI for acute myocardial infarction. However, bivalirudin was associated with a higher rate of acute stent thrombosis within 24 hours.

Related Editorial


Original Articles
Brief Report: Effect of Gene Therapy on Visual Function in Leber's Congenital Amaurosis

A form of Leber's congenital amaurosis is caused by mutant RPE65, a critical component of the visual cycle. Two early clinical trials to assess subretinal injection of a viral vector containing RPE65 in young adults with advanced retinal degeneration show that this approach is generally safe in the short term, although one group reported an adverse event: macular hole. The authors observed improvement in some measures of visual function.

Related Editorial


Original Articles
Brief Report: Safety and Efficacy of Gene Transfer for Leber's Congenital Amaurosis

A form of Leber's congenital amaurosis is caused by mutant RPE65, a critical component of the visual cycle. Two early clinical trials to assess subretinal injection of a viral vector containing RPE65 in young adults with advanced retinal degeneration show that this approach is generally safe in the short term, although one group reported an adverse event: macular hole. The authors observed improvement in some measures of visual function.

Related Editorial


Special Article
The Collective Dynamics of Smoking in a Large Social Network

The prevalence of smoking has decreased substantially in the United States over the past 30 years. This article examines the extent of person-to-person spread of smoking behavior and the extent to which groups of widely connected people quit together. Smoking behavior spreads through close and distant social ties, groups of interconnected people quit in concert, and smokers are increasingly marginalized socially.

Related Editorial


Clinical Therapeutics
Sublingual Immunotherapy

A 28-year-old man presents with allergic rhinitis, primarily due to grass pollen, that has not previously responded to antihistamines and nasal sprays. A trial of sublingual immunotherapy is recommended. Sublingual immunotherapy is more convenient than injection immunotherapy. However, only one agent, which is specific for grass-pollen allergies, has been approved for clinical use in some European countries. The Food and Drug Administration has not approved any agent for sublingual immunotherapy.


Case Records of the Massachusetts General Hospital
A Woman with Bone Pain

A 46-year-old woman was evaluated at this hospital because of pain in the right hip and leg of several months' duration. The patient had a history of celiac disease but was otherwise well. Imaging studies disclosed multiple bone lesions in the pelvis and long bones, with a diffuse abnormality in the bone marrow. Laboratory tests showed low serum calcium and elevated alkaline phosphatase levels. A diagnostic procedure was performed.


Clinical Implications of Basic Research
How HIV Guts the Immune System

The human immunodeficiency virus (HIV) binds an integrin receptor on CD4+ T cells in the gut.


HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.